A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-04-24
Adverse events
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-07-18 (study day 75); relationship: not assessed
Grade 3 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2023-08-30 (study day 118); relationship: not assessed; serious criteria: hospitalization
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-02 (study day 151); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-12 (study day 253); relationship: not assessed
Grade 1 Anaemia — outcome: UNKNOWN; onset 2024-01-28 (study day 269); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-06-03 (study day 396); relationship: not assessed
Data queries
No data queries.